Skip to main content
SpringerLink
Log in

Neue Entwicklungen bei antiallergischen Therapien und Therapiekonzepten

  • Chapter
Allergologie

  • 6537 Accesses

Zusammenfassung

Das immer detailliertere Verständnis zur Pathogenese der verschiedenen Erkrankungen, die in diesem Buch abgehandelt werden, erlaubt auch die gezieltere Therapie. Eine Voraussetzung ist oftmals die Stratifizierung der Patienten. Dies bedeutet, unter der Überschrift einer Erkrankungsentität immer spezifischere Subentitäten (Endotypen) auch gezielt behandeln zu können. Die Entschlüsselung von komplexen Zusammenhängen verschiedener Erkrankungen erlauben zudem die gezielte Neutralisierung oder Blockade ganz bestimmter Moleküle und Pathways. Auch bekannte Therapieverfahren werden optimiert, nach den neuesten Erkenntnissen modifiziert und in neuen Studiendesigns analysiert. In diesem Kapitel werden neue Therapieansätze, sich im Zulassungsverfahren befindliche neue Therapien sowie Konzepte vorgestellt. Die Darstellung umfasst Urtikaria, Anaphylaxie und Mastozytose, Ansätze zur atopischen Dermatitis, Konzepte zur allergischen Rhinitis und zum Asthma sowie den letzten Stand der Entwicklung zur spezifischen Immuntherapie.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Akdis M, Akdis CA (2007) Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 119: 780–791

    Google Scholar 

  • Barnes N, Pavord I, Chuchalin A et al. (2012) A randomized double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 42(1): 38–48

    Google Scholar 

  • Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suárez-Fariñas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371: 130–139

    Google Scholar 

  • Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG et al. (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117: 134–140

    Google Scholar 

  • Castro M, Mathur S, Hargreave F et al. (2011) Reslizumab for poorly controlled, eosinophilic asthma. A randomized, placebo-controlled study. Am J Respir Crit Care Med 184: 1125–1132

    Google Scholar 

  • Cavet ME, Volhejn S, Harrington KL, Zhang JZ (2013) Anti-allergic effects of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts and epithelial cells. Mol Vis 19: 1515–1525

    Google Scholar 

  • Corren J (2013) Anti-interleukin-13 antibody therapy for asthma: one step closer. Eur Respir J 41: 255–256

    Google Scholar 

  • Corren J, Lemaske RF, Hanania NA et al. (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365: 1088–1098

    Google Scholar 

  • Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R et al. (2006) Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 355: 1445–1455

    Google Scholar 

  • Darsow U, Brockow K, Pfab F, Jakob T, Petersson CJ, Borres M, Ring J, Behrendt H, Huss-Marp J (2014) Heterogeneity of molecular sensitization profiles in grass pollen allergy – implications for immunotherapy? Clin Exp Allergy 44: 778–786

    Google Scholar 

  • Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, Traidl-Hoffmann C, Behrendt H, Durham SR, Schmidt-Weber CB, Cavani A (2009) Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 119: 3573–3585

    Google Scholar 

  • Garcia G, Magnan A, Chiron R et al. (2013) A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 144: 411–419

    Google Scholar 

  • Gauvreau GM, Boulet L-P, Cockcroft DW et al. (2011) Effects of Interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Resp Crit Care Med 183: 1007–1014

    Google Scholar 

  • Ghazi A, Trikha A, Calhoun WJ (2012) Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma. Expert Opin Biol Ther 12: 113–118

    Google Scholar 

  • Gueniche A, Knaudt B, Schuck E, Volz T, Bastien P, Martin R, Röcken M, Breton L, Biedermann T (2008) Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 159(6): 1357–1363

    Google Scholar 

  • Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O (2005) Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116: 608–613

    Google Scholar 

  • Jutel M, Van de Veen W, Agache I, Azkur KA, Akdis M, Akdis CA (2013) Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development. Allergol Int 62: 425–433

    Google Scholar 

  • Karamloo F, Schmid-Grendelmeier P, Kussebi F, Akdis M, Salagianni M, von Beust BR et al. (2005) Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur J Immunol 35: 3268–3276

    Google Scholar 

  • Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A et al. (2006) Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 117: 1470–1476

    Google Scholar 

  • Kussebi F, Karamloo F, Rhyner C, Schmid-Grendelmeier P, Salagianni M, Mannhart C et al. (2005) A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 115: 323–329

    Google Scholar 

  • Larche M (2006) Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr Opin Immunol 18: 745–750

    Google Scholar 

  • Massanari M, Nelson H, Casale T et al. (2010) Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 125: 383–389

    Google Scholar 

  • Moingeon P (2012) Adjuvants for allergy vaccines. Hum Vaccin Immunother 8(10): 1492–1498

    Google Scholar 

  • Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P et al. (2004) Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 101(suppl 2): 14677–14682

    Google Scholar 

  • Niespodziana K, Focke-Tejkl M, Linhart B et al. (2011) A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol 127: 1562–1570

    Google Scholar 

  • Noonan M, Korenblat P, Mosesova S et al. (2013) Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 132: 567–574

    Google Scholar 

  • Oh CK, Leigh R, McLaurin KK et al. (2013) A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir Res 14: 93

    Google Scholar 

  • Pavord ID, Korn S, Howarth P et al. (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicenter, double-blind, placebo-controlled trial. Lancet 380: 651–659

    Google Scholar 

  • Piper E, Brightling C, Niven R et al. (2012) A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Resp J 41: 330–338

    Google Scholar 

  • Pree I, Reisinger J, Focke M et al. (2007) Analysis of epitopespecificimmune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol 179: 5309–5316

    Google Scholar 

  • Sel S, Wegmann M, Dicke T et al. (2008) Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J Allergy Clin Immunol 121: 910–916

    Google Scholar 

  • Senti G, Prinz Vavricka BM, Erdmann I et al. (2008) Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 105: 17908–17912

    Google Scholar 

  • Senti G, von Moos S, Tay F et al. (2012a) Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 129: 128–35

    Google Scholar 

  • Senti G, Crameri R, Kuster D et al. (2012b) Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 129: 1290–1296

    Google Scholar 

  • Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT (2004) Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 113: 1144–1151

    Google Scholar 

  • Spertini F, Perrin Y, Audran R, Pellaton C, Boudousquié C, Barbier N, Thierry AC, Charlon V, Reymond C (2014) Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides. J Allergy Clin Immunol 134: 239–240

    Google Scholar 

  • Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T, Itai A, Matsuda H (2ßß5) A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105: 2324–2331

    Google Scholar 

  • Tedeschi A, Kolkhir P, Asero R, Pogorelov D, Olisova O, Kochergin N, Cugno M (2014) Chronic urticaria and coagulation: pathophysiological and clinical aspects. Allergy 69(6): 683–691

    Google Scholar 

  • Valenta R, Niederberger V (2007) Recombinant allergens for immunotherapy. J Allergy Clin Immunol 119: 826–830

    Google Scholar 

  • Volz T, Skabytska Y, Guenova E, Chen KM, Frick JS, Kirschning CJ, Kaesler S, Röcken M, Biedermann T (2014) Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. J Invest Dermatol 134(1): 96–104

    Google Scholar 

  • Wenzel S, Wilbraham D, Fuller R et al. (2007) Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370: 1422–1431

    Google Scholar 

  • Wenzel S, Ford L, Pearlman D et al. (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368(26): 2455–2466

    Google Scholar 

  • Worm M, Lee HH, Kleine-Tebbe J et al. (2011) Development and preliminary clinical evaluation of a peptide immunotherapyvaccine for cat allergy. J Allergy Clin Immunol 127: 89–97

    Google Scholar 

  • Zeskind B (2011) Lebrikizumab treatment in adults with asthma. N Engl J Med 365: 2432–2434

    Google Scholar 

Weiterführende Literatur

  • Akin C, Brockow K, D’Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, Metcalfe DD (2003) Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31: 686–692

    Google Scholar 

  • Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD (2004) A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103: 3222–3225

    Google Scholar 

  • Brockow K, Grosber M, Hölzle K, Behrendt H, Ring J (2009) Neues zur Therapie der Mastozytose. Akt Dermatol 12: 491–495

    Google Scholar 

  • Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD (2007) Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 119: 1550–1551

    Google Scholar 

  • Damaj G, Bernit E, Ghez D, Claisse JF, Schleinitz N, Harle JR, Canioni D, Hermine O (2008) Thalidomide in advanced mastocytosis. Br J Haematol 141: 249–253

    Google Scholar 

  • Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P (2007) Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 92: 1451–1459

    Google Scholar 

  • Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutre SE (2005) Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106: 2865–2870

    Google Scholar 

  • Hartmann K, Siebenhaar F, Belloni B, Brockow K, Eben R, Hartmann B, Ruëff F, Schoepke N, Staubach P, Weber A, Maurer M (2010) Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 162(1): 185–190

    Google Scholar 

  • Kluin-Nelemans HC, Ferenc V, van Doormaal JJ, van Iperen C, Peters WG, Akin C, Valent P (2009) Lenalidomide therapy in systemic mastocytosis. Leuk Res 33(3): e19–22

    Google Scholar 

  • Kontou-Fili K (2008) High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 63: 376–378

    Google Scholar 

  • Nakamura R, Chakrabarti S, Akin C, Robyn J, Bahceci E, Greene A, Childs R, Dunbar CE, Metcalfe DD, Barrett AJ (2006) A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 37: 353–358

    Google Scholar 

  • Quintas-Cardama A, Kantarjian H, Verstovsek S (2007) Treatment of systemic mastocytosis with denileukin diftitox. Am J Hematol 82: 1124

    Google Scholar 

  • Schatz M, Verhoef G, Gattermann N, Ottmann OG, Schimansky T, Alland L, Rafferty T, Gratwohl A, Follows G, Hochhaus A (2006) A phase II study of AMN107, a novel tyrosine kinase inhibitor, administered to patients (pts) with systemic mastocytosis (SM). J Clin Oncol 24: 6588 (Abstr.)

    Google Scholar 

  • Siebenhaar F, Kuhn W, Zuberbier T, Maurer M (2007) Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol 120: 213–215

    Google Scholar 

  • Soriano Gomis V, Gonzalez Delgado P, Niveiro Hernandez E (2008) Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J Investig Allergol Clin Immunol 18: 225–226

    Google Scholar 

  • Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NA, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37: 435–453

    Google Scholar 

  • Verstovsek S, Akin C, Manshouri T, Quintas-Cardama A, Huynh L, Manley P, Tefferi A, Cortes J, Giles FJ, Kantarjian H (2006) Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 30: 1365–1370

    Google Scholar 

  • Verstovsek S, Tefferi A, Cortes J, O’Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H (2008) Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14: 3906–3915

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Laboratoriumsmedizin und Pathobiochemie, Molekuldiagnostik, Universitätsklinikum Gießen und Marburg GmbH, Baldingerstraße, 35043, Marburg, Deutschland

    H. Renz Prof. Dr. med.

  2. Klinik und Poliklinik für Dermatologie und Allergologie; Klinikum rechts der Isar, Technischen Universität München, Biedersteinerstraße 29, 80802, München, Deutschland

    T. Biedermann Prof. Dr. med.

  3. Universitäts-Hautklinik, Eberhard Karls Universität, Liebermeisterstraße 25, 72076, Tübingen, Deutschland

    M. Röcken Prof. Dr. med.

Authors
  1. M. Röcken Prof. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Biedermann Prof. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Renz Prof. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinikum rechts der Isar, Technischen Universität München, München

    Tilo Biedermann

  2. Städtisches Klinikum Karlsruhe, Karlsruhe

    Werner Heppt

  3. Universitätsklinikum Gießen und Marburg GmbH, Marburg

    Harald Renz

  4. Universitätsklinikum Tübingen, Eberhard Karls Universität, Tübingen

    Martin Röcken

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Röcken, M., Biedermann, T., Renz, H. (2016). Neue Entwicklungen bei antiallergischen Therapien und Therapiekonzepten. In: Biedermann, T., Heppt, W., Renz, H., Röcken, M. (eds) Allergologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37203-2_59

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37203-2_59

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37202-5

  • Online ISBN: 978-3-642-37203-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation